- |||||||||| Opdivo (nivolumab) / Ono Pharma, BMS, lenvatinib / Generic mfg., Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen
Journal: Renal cell carcinoma: molecular characterization and evolving treatment paradigms. (Pubmed Central) - Mar 3, 2017 The addition of several new agents effective in metastatic RCC has resulted in improvements in overall survival; however, there are few avenues to durable responses or cure. Ongoing studies as well advances in our understanding of the molecular alterations underlying distinct forms of RCC promise further therapeutic advances and have the potential to alter the current treatment paradigm.
- |||||||||| Journal: EGF Induced RET Inhibitor Resistance in CCDC6-RET Lung Cancer Cells. (Pubmed Central) - Feb 24, 2017
EGF could trigger resistance to RET inhibition in CCDC6-RET lung cancer cells, and endothelial cells may confer resistance to RET inhibitors by EGF. E7080 and other RET inhibitors may provide therapeutic benefits in the treatment of RET-positive lung cancer patients.
- |||||||||| Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
Trial initiation date, PD(L)-1 Biomarker: Lenvatinib and Pembrolizumab in Differentiated Thyroid Cancers (DTC) (clinicaltrials.gov) - Jan 26, 2017 P2, N=60, Not yet recruiting, E7080 and other RET inhibitors may provide therapeutic benefits in the treatment of RET-positive lung cancer patients. Initiation date: Jan 2017 --> Apr 2017
- |||||||||| Lenvima (lenvatinib) / Eisai, Merck (MSD)
Enrollment closed, Enrollment change, Trial initiation date, Metastases: Phase 1 Study to Determine the Effect of Lenvatinib (E7080) on the Pharmacokinetics of Midazolam in Subjects With Advanced Solid Tumors (clinicaltrials.gov) - Dec 14, 2016 P1, N=22, Active, not recruiting, Phase classification: P1/2 --> P1b/2 | N=150 --> 250 Recruiting --> Active, not recruiting | N=18 --> 22 | Initiation date: Jan 2016 --> May 2016
- |||||||||| Halaven (eribulin mesylate) / Eisai, Lenvima (lenvatinib) / Eisai, Merck (MSD)
Enrollment open, Trial initiation date, Metastases: Eribulin and Lenvatinib in Advanced Solid Tumors (clinicaltrials.gov) - Jul 23, 2016 P2, N=39, Recruiting, Recruiting --> Active, not recruiting | N=210 --> 29 Not yet recruiting --> Recruiting | Initiation date: Jan 2016 --> May 2016
- |||||||||| Lenvima (lenvatinib) / Eisai, Merck (MSD)
Trial completion, Trial initiation date, Trial primary completion date: A Study in Subjects With Recurrent Malignant Glioma (clinicaltrials.gov) - May 23, 2016 P2, N=151, Completed, Not yet recruiting --> Recruiting Terminated --> Completed | Initiation date: Aug 2010 --> Nov 2010 | Trial primary completion date: Dec 2013 --> Mar 2013
|